A:  Metallomix Inc. is a clinical stage biotech company targeting isotopic dysfunction – a previously unrecognized driver of cancer and diseases of aging including neurodegenerative diseases. The metallome – metals in human biology and disease – plays an integral role in various biological functions, including amino acid and protein synthesis, DNA integrity and repair, and mitochondrial metabolism.  We are leading the way in illuminating a metallome much more nuanced than simply the function of specific metals or oxidation states, offering a massive and previously unexplored opportunity for drug discovery and development. 

A:  Our mission is to bring forward new medicines through understanding the isotopic dysfractionation and developing safe, effective, and clinically derisked small molecular isotopic modulators. 

A:  Our goal is to become The #1 company in isotopic metallomics focused on developing inherently safe, effective, and clinically derisked, disease modifying therapies for treatment of complex diseases.

A: We have agreed to make available to each prospective investor the opportunity to ask questions and to receive answers from our officers concerning the terms and conditions of investing into our business, and to obtain any additional information, to the extent we possess such information or can acquire it without unreasonable effort or expense. You may mail or email your questions, inquiries, and requests to: